173 related articles for article (PubMed ID: 17107608)
1. Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.
Palmieri G; Satriano SM; Budroni M; Cossu A; Tanda F; Canzanella S; Caracò C; Simeone E; Daponte A; Mozzillo N; Comella G; Castello G; Ascierto PA
BMC Cancer; 2006 Nov; 6():266. PubMed ID: 17107608
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
4. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
5. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
6. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients.
Kammula US; Ghossein R; Bhattacharya S; Coit DG
J Clin Oncol; 2004 Oct; 22(19):3989-96. PubMed ID: 15459222
[TBL] [Abstract][Full Text] [Related]
7. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
[TBL] [Abstract][Full Text] [Related]
8. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
9. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients.
Mellado B; Gutierrez L; Castel T; Colomer D; Fontanillas M; Castro J; Estapé J
Clin Cancer Res; 1999 Jul; 5(7):1843-8. PubMed ID: 10430090
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
[TBL] [Abstract][Full Text] [Related]
12. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients.
Baldi A; Dragonetti E; Battista T; Groeger AM; Esposito V; Baldi G; Santini D
Anticancer Res; 2000; 20(5C):3923-8. PubMed ID: 11268478
[TBL] [Abstract][Full Text] [Related]
15. Detection of tyrosinase mRNA from the blood of melanoma patients.
Stevens GL; Scheer WD; Levine EA
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
17. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study.
Callejo SA; Antecka E; Blanco PL; Edelstein C; Burnier MN
Eye (Lond); 2007 Jun; 21(6):752-9. PubMed ID: 16575415
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
[TBL] [Abstract][Full Text] [Related]
19. Tumour microdissemination and survival in metastatic melanoma.
Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Franzke A; Sel S; Atzpodien E; Buer J
Anticancer Res; 2000; 20(5B):3619-24. PubMed ID: 11131671
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.
Hoon DS; Bostick P; Kuo C; Okamoto T; Wang HJ; Elashoff R; Morton DL
Cancer Res; 2000 Apr; 60(8):2253-7. PubMed ID: 10786692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]